OptimizeRx (OPRX) Aandeel Koers
OptimizeRx Koers
De omzet is de afgelopen 18 jaar met 47,5% per jaar gegroeid tot 109,43 Miljoen USD. De winst per aandeel is de afgelopen 12 jaar met 17,4% per jaar gegroeid. De nettowinstmarge van OptimizeRx ligt op 4,7% en is ten opzichte van 0,6% enkele jaren eerder gestegen. Analisten hanteren een mediaan koersdoel van 11,00 USD — dat impliceert 24,0% boven de huidige koers. Van de 12 analisten geven 11 het aandeel een koopadvies — per saldo een Kopen-consensus.
OptimizeRx aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
OptimizeRx bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over OptimizeRx
Some of the main competitors of OPTIMIZERx Corp in the market include Updox, Allscripts Healthcare Solutions, and NextGen Healthcare.
The business model of OPTIMIZERx Corp is focused on providing software solutions and technology platforms to the healthcare industry. The company offers a comprehensive suite of services, including electronic prescribing for healthcare providers, patient engagement and adherence tools, as well as financial assistance programs for patients to help them access and afford medication. OPTIMIZERx Corp's innovative technology enables pharmaceutical manufacturers to effectively engage with healthcare professionals and patients, improving patient outcomes and reducing healthcare costs. With its unique offerings and solutions, OPTIMIZERx Corp aims to optimize the connection between patients, healthcare providers, and pharmaceutical companies in the healthcare ecosystem.
OPTIMIZERx Corp is primarily active in the healthcare and pharmaceutical industries.
OPTIMIZERx Corp is a renowned digital health company that specializes in providing software solutions to streamline the pharmaceutical industry. Founded in 2006, OPTIMIZERx has established itself as a leader in the field, offering innovative platforms to enhance patient engagement and adherence. With a focus on improving communication between healthcare providers, pharmaceutical companies, and patients, OPTIMIZERx's solutions enable physicians to deliver cost-effective and personalized care. The company has consistently grown its presence by incorporating cutting-edge technologies and strategic partnerships, ensuring it stays at the forefront of the industry. OPTIMIZERx Corp's commitment to improving patient outcomes has made it a trusted name in the digital health sector.
OPTIMIZERx Corp, a leading provider of digital health communication solutions, has achieved several significant milestones. The company experienced impressive revenue growth, surpassing $30 million in annual revenue in 2020. In addition, OPTIMIZERx Corp expanded its client base, forging partnerships with renowned pharmaceutical manufacturers, healthcare providers, and pharmacies. The company launched innovative solutions, such as its SampleRx platform, which allows patients to access cost-saving coupons and trial offers for prescription medications. OPTIMIZERx Corp also made strategic acquisitions, augmenting its capabilities and expanding its market reach. These milestones demonstrate the company's commitment to revolutionizing patient engagement and improving prescription affordability in the healthcare industry.
OPTIMIZERx Corp is primarily present in the United States.
Optimizerx Corp represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on improving patient access to life-saving therapies, Optimizerx Corp aims to enhance the healthcare ecosystem through its digital platform and strategic partnerships. Committed to delivering superior solutions and services, the company leverages cutting-edge technology and data-driven insights to empower patients, healthcare providers, and pharmaceutical manufacturers. Optimizerx Corp strives to optimize the healthcare experience, driving better outcomes, cost-savings, and improved patient adherence. As a trusted leader in the industry, Optimizerx Corp demonstrates a dedication to excellence, integrity, and creating value for its shareholders, healthcare partners, and the overall community.
Analisten hanteren momenteel een gemiddeld koersdoel van 10,25 USD voor het aandeel OptimizeRx (mediaan: 11,00 USD), oftewel +15,6 % ten opzichte van de laatste koers. De consensus is gebaseerd op 12 analistenratings.
12 analisten beoordelen het aandeel OptimizeRx momenteel: 11 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat OptimizeRx een omzet van 96,23 Miljoen USD en winst per aandeel van 0,84 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel OptimizeRx op 8,01 EUR (8,87 USD).
Het aandeel OptimizeRx (OPRX) is genoteerd aan 1 beurzen, waaronder: NASDAQ (OPRX).
The OPTIMIZERx Corp is a leading provider of digital solutions to improve patient communication, adherence, and access to medications. The company is headquartered in Rochester, Michigan and works with numerous pharmaceutical manufacturers, insurers, and pharmacies to optimize healthcare. One of OPTIMIZERx's main products is the Sample Fulfillment System (SFS), a paperless system for ordering and delivering medication samples to doctors. Doctors can access a wide range of medications, order samples, and effectively treat their patients through the system. The SFS is easy to use and provides doctors with a convenient way to receive medications and care for patients. OPTIMIZERx also offers a variety of patient communication solutions to improve compliance and adherence. The OPTIMIZERx portal is an online portal that allows patients to order and manage medications, as well as receive information about their medications and their side effects. The portal is user-friendly and easy to navigate, allowing patients to securely access their medical information. Another important area of OPTIMIZERx is supporting patients with coupons and discounts on prescription medications. OPTIMIZERx offers discount programs for a variety of medications to help patients manage the high costs of their medications. Similarly, OPTIMIZERx offers various options to assist patients in applying for discounts and ensuring they receive the best offer. In addition, OPTIMIZERx also provides communication solutions for pharmacies to improve information exchange and collaboration between pharmacies and doctors. The OPTIMIZERx eCoupon system allows pharmacies to pass on discounts and coupons directly to patients. In summary, the OPTIMIZERx Corp offers a wide range of digital solutions to improve patient communication, increase adherence and compliance, and facilitate access to medications. The company works closely with pharmaceutical manufacturers and other healthcare providers to optimize healthcare and provide the best possible support for patients.
De verwachte omzet van OptimizeRx bedraagt 96,23 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van OptimizeRx bedraagt 16,33 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van OptimizeRx bedraagt momenteel 10,53. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het OptimizeRx-aandeel in te schatten.
De koers-omzetverhouding (P/S) van OptimizeRx bedraagt momenteel 1,79. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het OptimizeRx-aandeel.
De Eulerpool Kwaliteitsscore voor OptimizeRx is 5/10.
De ISIN van OptimizeRx is US68401U2042. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van OptimizeRx is A2JL4Z. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van OptimizeRx is OPRX. Onder dit beurstickersymbool wordt het OptimizeRx-aandeel op de beurs verhandeld.
OptimizeRx aandeel
OptimizeRx Peer Group
OptimizeRx Ticker
OptimizeRx FIGI
Alle fundamentals en diepgaande analyse van OptimizeRx
Onze aandelenanalyse van het OptimizeRx-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van OptimizeRx. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: